Korea Investment CORP Purchases 58,200 Shares of Becton, Dickinson and Company $BDX

Korea Investment CORP boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 130.1% during the 2nd quarter, Holdings Channel reports. The firm owned 102,924 shares of the medical instruments supplier’s stock after buying an additional 58,200 shares during the period. Korea Investment CORP’s holdings in Becton, Dickinson and Company were worth $15,575,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Auto Owners Insurance Co increased its holdings in shares of Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after buying an additional 40,528,680 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at approximately $3,721,533,000. Wellington Management Group LLP lifted its stake in shares of Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after purchasing an additional 5,174,944 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Becton, Dickinson and Company by 13.0% during the 4th quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after purchasing an additional 4,223,149 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its holdings in Becton, Dickinson and Company by 23,219.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after buying an additional 4,137,888 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on BDX shares. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research report on Monday, July 6th. Royal Bank Of Canada upped their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. UBS Group assumed coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target for the company. Jefferies Financial Group restated a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Finally, Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $185.67.

Insider Activity

In related news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 11,779 shares of company stock valued at $1,974,669. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.0%

Shares of Becton, Dickinson and Company stock opened at $191.95 on Monday. The firm’s 50 day simple moving average is $161.58 and its two-hundred day simple moving average is $160.84. The firm has a market capitalization of $52.89 billion, a price-to-earnings ratio of 57.82, a PEG ratio of 13.53 and a beta of 0.19. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $192.30. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the firm posted $3.68 earnings per share. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 126.51%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.